SCHEMBL3247458

SCHEMBL3247458

COc1cccc(S(=O)(=O)Nc2ccc(Cl)cc2Cc2ccccc2Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.58
NFE2L2 Q16236 2/20 0.58
FLT1 P17948 1/20 0.53
FLT4 P35916 1/20 0.53
KDR P35968 1/20 0.53
PGR P06401 4/20 0.48
FFAR4 Q5NUL3 1/20 0.46
KDM1A O60341 1/20 0.46
MAOA P21397 1/20 0.46
GLO1 Q04760 1/20 0.46
SLC40A1 Q9NP59 1/20 0.46
ERBB2 P04626 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
PGAM1 P18669 1/20 0.45
PTGES2 Q9H7Z7 1/20 0.45
LMNA P02545 2/20 0.45
TRIM24 O15164 1/20 0.44
BRD1 O95696 1/20 0.44
BRPF1 P55201 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247467 0.89 LMNA (0.58) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3251866 0.87 KEAP1 (0.53) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3255565 0.84 MEP1B (0.55) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3252007 0.80 TSHR (0.58) PTGES2
SCHEMBL3256105 0.77 ALDH1A1 (0.65) KEAP1NFE2L2LMNAHTTNPSR1
SCHEMBL3081790 0.76 LMNA (0.67) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL3247611 0.76 TSHR (0.46) FLT1FLT4KDRLMNAHTT
SCHEMBL3250123 0.75 MAPK1 (0.60) KEAP1NFE2L2FFAR4LMNAHTT
SCHEMBL20561080 0.74 FLT1 (0.61) KEAP1NFE2L2FLT1FLT4KDR
SCHEMBL12945621 0.74 KEAP1 (0.61) KEAP1NFE2L2PGRFFAR4GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885FLT1 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.